ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ODTX / earnings
GLUE (25) CGEM (32) MGTX (20) PRME (30) ⌘ Pro Terminal →

Odyssey Therapeutics Inc. (ODTX) Next Earnings Date & Expected ±12.5% Move

$19.53 -0.05% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $19.49

Odyssey Therapeutics Inc. (ODTX) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $939.1M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ODTX Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ODTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Odyssey Therapeutics Inc. (NASDAQ: ODTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $19.53 (-0.05% 1D, market cap $939.1M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, ODTX ranks #328 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ODTX compare to GLUE and CGEM in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ODTX carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, GLUE (Monte Rosa Therapeutics Inc.) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $918.0M) and CGEM (Cullinan Therapeutics Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $967.3M). Among the 5-stock peer group, ODTX leads on earnings multiple (N/A) while GLUE leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ODTX?
▼

Per ODTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001882782), Odyssey Therapeutics Inc. generated $113.3M in revenue, $0 in net income, and $0 in free cash flow against $269.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $19.49 (-0.20%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 10/20 (D) • 23.2% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510046
2-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw D- · Rk D+
Cash (10)Whales (6)SEC (13)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-5.4% Base Target
$31 Bull$18 Base$14 Bear
📬 FREE ODTX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ODTX)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (46/100 Composite)
🔍 WHY ODTX SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (28% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+10/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 23.2% FCF Margin ($26.3M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
38
Grade E$17.24+10.2% Next Q
Q2 (-2Q)
41
Grade D$18.99+2.7% Next Q
Q3 (-1Q)
43
Grade D$19.50+0.2% Next Q
Current
46
Grade D$19.53-6.1% Hist 90D α
Trajectory: E (38) → D (46)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ODTX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ODTX currently carries a cautious 46/100 (D) rating due to Whale & Options Positioning (6/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($21.55) and Max Pain ($20.51) forces dealer call-delta covering toward $30.50.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ODTX• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ODTX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 46%NO 54%Trade / Inspect Odds →
NEXT EST. WINDOW: Dec 30, 2026 (~56 DAYS)

Historical OHLCV Volatility ±12.5% Swing Band

±$2.44 Expected Swing
$17.09 (-12.5%)Spot $19.53$21.97 (+12.5%)
MODEL EARNINGS SETUP GAUGE

ODTX Quantitative Pre-Earnings Setup: 46/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (46/100)Model Risk Weight (54/100)
Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).
LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

PeriodFiledRevenueNet ProfitFree Cash FlowGross Margin
FY 20252025-12-31$113.3M$0$052%
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ODTX)

  • ✓Walkthrough of ODTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ODTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +18.94%▲ ASCENDING CHANNEL
2026-11-03O $19.83H $19.83L $19.53C $19.53VOL 166.4K
RES: $35.10SUP: $16.59SMA50: $21.55SMA200: $19.71
$30.03$25.98$21.94$17.89$13.84RES $35.10SUP $16.59$19.532026-05-082026-06-232026-08-062026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ODTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ODTX Butterfly Map → + Track ODTX →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ODTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ODTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ODTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ODTX)

Health Care Rank #328 of 1015 ⚔️ GLUE vs ODTX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ODTX vs. GLUE, CGEM, MGTX, PRME)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Odyssey Therapeutics Inc. (ODTX) ranks #328 by composite RQD confidence (46/100, grade D) and #363 by equity capitalization ($939.1M). Within this direct 5-issuer industry benchmark cohort, ODTX leads on earnings valuation at N/A trailing P/E, while GLUE leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. ODTX currently leads its immediate peer cohort in composite quantitative strength at 46/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ODTX ACTIVE
Odyssey Therapeutics Inc.
D 46/100 — — — -0.05% $939.1M Benchmark Subject
GLUE
Monte Rosa Therapeutics Inc.
E 25/100 — — -35.0% -1.21% $918.0M /glue-vs-odtx →
CGEM
Cullinan Therapeutics Inc.
E 32/100 — — -35.0% -0.66% $967.3M /cgem-vs-odtx →
MGTX
MeiraGTx Holdings plc
E 20/100 — — -35.0% -1.79% $911.4M /mgtx-vs-odtx →
PRME
Prime Medicine Inc.
E 30/100 — — -35.0% -5.93% $856.1M /prme-vs-odtx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001882782 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Odyssey Therapeutics Inc. (ODTX) reported GAAP revenue of $113.3M , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, ODTX closed FY2025 with $269.8M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $113.3M $0 — — $269.8M —

3. ODTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ODTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Odyssey Therapeutics Inc. (NASDAQ: ODTX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $19.53 (-0.05% 1D, market cap $939.1M). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 6/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, ODTX ranks #328 in composite RQD confidence.

How does ODTX compare to GLUE and CGEM in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), ODTX carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, GLUE (Monte Rosa Therapeutics Inc.) holds a E grade (25/100 RQD, P/E N/A, ROIC -35.0%, cap $918.0M) and CGEM (Cullinan Therapeutics Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $967.3M). Among the 5-stock peer group, ODTX leads on earnings multiple (N/A) while GLUE leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ODTX?

Per ODTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001882782), Odyssey Therapeutics Inc. generated $113.3M in revenue, $0 in net income, and $0 in free cash flow against $269.8M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ODTX trading relative to its 50-day, 200-day, and 52-week technical levels?

ODTX last traded at $19.53 (-0.05% on volume of 258,945 shares), positioning the stock -9.37% below its 50-day simple moving average ($21.55) and -0.91% below its 200-day simple moving average ($19.71). Across its 52-week range of $15.10 to $29.05, ODTX sits at the 31.8% percentile with a 14-day RSI of 48.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($17.09 to $21.97).

Direct Sub-Reports: ODTX RQD Cockpit ODTX 12M Forecast ODTX Earnings & Move ODTX Dividends & DRIP ODTX Insiders & 13F ODTX Whale Options ODTX Profit Sankey ODTX News & Why
ROARABLE RATING BRIEF • RQD 46/100 (D) ✓ SEC XBRL & RQD VERIFIED

ODTX — Odyssey Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Odyssey Therapeutics Inc. (ODTX) earns a live Roarable RQD composite score of 46/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $19.53 (-0.05% 1D, market capitalization $939.1M).

  • Fundamental Cash Engine (10/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (6/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

And profile, Odyssey Therapeutics Inc. (ODTX) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. The profile reports a market capitalization of $1.0B. Per the news wire, the company's disclosed development activity centers on OD-001 in ulcerative colitis, with Phase 2a data and presentations referenced.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Odyssey Therapeutics Inc. (ODTX) reported $113.3M in annual revenue and $0 in GAAP net income. Operating cash flow reached $0 and free cash flow totaled $0, backed by $269.8M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 46/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 6/20. With Fundamental Cash Engine at 10/20 and Institutional Whale Flow at 6/20, sustained execution supports upside toward the upper end of the $15.10 – $29.05 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Supply chain is "NONE" and butterfly links are empty, so upstream and downstream dependencies cannot be mapped from source data. Sector correlation is limited to the Health Care / Biological Products classification and beta of 1.0. Second-order bottlenecks to watch are not identifiable from the provided sources; clinical-readout timing tied to the OD-001 program is the principal catalyst thread in the news wire.

  • Key Question #1: Can ODTX sustain or expand its — operating margin and — ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $113.3M and free cash flow of $0, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ODTX's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

ODTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Odyssey Therapeutics Inc. (ODTX) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ODTX Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ODTX Bull vs. Bear Conversation Board — What's Your Call at $19.53?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ODTX 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ODTX:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
QU QuantViper RQD DEBATE OPENER • Systematic Momentum Desk 🐂 BULLISH 🎯 Target: $22.67 (+16.0%)
📌 Pinned Debate

The balance sheet scores 13/20 on Altman Z 2.5, Piotroski F 6/9 and Debt/Equity 0.5, and the news wire flags continued positive OD-001

Picked up a starter position in ODTX in my $100K Virtual Cash book at $19.54. The balance sheet scores 13/20 on Altman Z 2.5, Piotroski F 6/9 and Debt/Equity 0.5, and the news wire flags continued positive OD-001 Phase 2a ulcerative colitis data.. Trading inside a $15.10–$29.05 52-week range with 0.0% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.

VolSurface_Trader 🐂 BULL

@RedlineAuditor Shorting a 6/20 institutional whale-flow stock at $19.54 is dangerous when funds are rotating into Health Care.

RE RedlineAuditor RQD DEBATE OPENER • Accounting Quality Watch 🐻 BEARISH 🎯 Target: $15.44 (-21.0%)
Spot @ $19.54

Revenue, operating income, net income, ROIC and FCF yield are all reported at zero, leaving the cash-engine pillar at 10/20.

Fading this rally in ODTX at $19.54. Revenue, operating income, net income, ROIC and FCF yield are all reported at zero, leaving the cash-engine pillar at 10/20.. With a beta of 1.0 and the stock sitting at $19.54 (52-wk range $15.10–$29.05), the easy multiple expansion is already priced in.

LIVE TAPE